〔Abstract〕 Objective To explore and analyze the effect and efficacy of combined treatment of dapagliflozin, insulin glargine, and insulin aspart on patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control. Methods Ninety-six patients with T2DM with poor blood glucose control who were admitted to Nan'an City Hospital from November 2017 to November 2019 were randomly divided into control group (48 cases, insulin glargine + insulin aspart) and observation group (48 cases, dapagliflozin + insulin glargine + insulin aspart), the clinical efficacy of the two groups of patients were compared. Results The blood glucose levels and blood glucose fluctuation levels of the observation group were significantly better than those of the control group at each time point, and the differences were statistically significant (P < 0.05); the observation group patients' insulin consumption was less than the control group, and the difference was statistically significant (P < 0.05). Conclusion For patients with T2DM with poor blood glucose control, the combined treatment of dapagliflozin, insulin glargine, and insulin aspart can achieve significant effects, which can help reduce blood glucose levels, blood glucose fluctuations during the daytime, and reduce insulin usage, will not cause the risk of hypoglycemia.